Whether you're considering self-funded launches or out-licensing, our model provides comprehensive simulations of potential benefits, enhancing your strategic decision-making process in commercialization.
Our real-time interactive dashboard covers your regular needs for summarizing extracted data from analyzed publications, automatically updating as new research is added.
We offer an advanced value communication tool that allows you to dynamically create custom scenarios, maximizes the efficiency and guarantees highly engaging meetings with the payers.
We offer an advanced value communication tool that allows you to dynamically create custom scenarios, maximizes the efficiency and guarantees highly engaging meetings with the payers.
Input top line project details and select the deliverable of interest and you'll receive a ballpark quote immediately, no commitment necessary! Our RFP Builder is the dawn of a new era in HEOR pricing transparency
We provide fast, flexible, and affordable solutions by asking open-ended questions based on the critique of clinical trial programs and economic models.
Our team of experts are available to discuss our products and services at stand #1800 in the main exhibition hall.
Eric Matckie
Chief Growth Officer at Herspeigel
Talk to Eric about:
Launch readiness and execution
Post-market reimbursement
Rare disease data and insights platform
Karl Freemyer
Head of Business Development
Talk to Karl about:
AI-assisted SLRs
Digital Modelling Dashboards
PICOs Prediction for Joint Clinical Assessment
Andrew Revel
Director of Business Development
Talk to Andrew about:
HEOR and Market Access Solutions
Partnership Strategies
Early Value Assessment of Assets
Richard Tolley
Head of Client Partnerships
Talk to Richard about:
Pricing, Reimbursement and Market Access solutions
Value Assessment and Communication
Payer Evidence Strategy
Lawrence Murphy
Director of Business Development
Talk to Lawrence about:
HTA submissions
Early Value Assessments
Joint Clinical Assessment (JCA)
Andrew Laws
Senior Director of Client Partnerships
Talk to Andrew about:
US Product Launch Strategy
IRA and ICER Preparedness
Joint Clinical Assessment (JCA)
Dawn Lee
Strategic Council Member
Talk to Dawn about:
Successful UK HTA submissions
Treatment Sequencing / Pathways Models
NICE Guidelines
Our Research & Posters
We will be presenting on a poster this year, focused on generalised cost-effectiveness analysis (GCEA), with the aim of identifying relevant payer archetypes and assessing how GCEA value elements can inform decision-making.
Poster Session 3
Date: Thursday, May 15
Poster session time: 10:30AM-1:30PM
Discussion period: 11:30 AM - 12:15 PM
PT22: Payer archetypes and decision-making in the United States (US): A framework for generalised cost-effectiveness analysis (GCEA) value elements to optimize patient access and equity.
